"\n\nMolGod<\/database>MOL-GOD<\/source-app>1<\/rec-number>17<\/ref-type>Gutierrez J<\/author>Eisenberg RL<\/author>Koval NJ et al.<\/author><\/authors><\/contributors>Pemoline and tetramisole 'positives' in english racehorses following levamisole administration.<\/title><secondary-title>Irish veterinary journal<\/secondary-title><\/titles><dates><year>2010<\/year><\/dates><electronic-resource-num>10.1186\/2046-0481-63-8-498<\/electronic-resource-num><urls><related-urls><url>https:\/\/core.ac.uk\/download\/270036038.pdf<\/url><\/related-urls><\/urls><\/record>\n<record><database name=\"MolGod\">MolGod<\/database><source-app name=\"MOL-GOD\" version=\"3.1.4\">MOL-GOD<\/source-app><rec-number>2<\/rec-number><ref-type name=\"Journal Article\">17<\/ref-type><contributors><authors><author>et al.<\/author><\/authors><\/contributors><titles><title>The effects of amantadine and pemoline on cognitive functioning in multiple sclerosis.<\/title><secondary-title><\/secondary-title><\/titles><dates><year>1996<\/year><\/dates><electronic-resource-num>10.1001\/archneur.1996.00550020101021<\/electronic-resource-num><\/record>\n<record><database name=\"MolGod\">MolGod<\/database><source-app name=\"MOL-GOD\" version=\"3.1.4\">MOL-GOD<\/source-app><rec-number>3<\/rec-number><ref-type name=\"Journal Article\">17<\/ref-type><contributors><authors><author>et al.<\/author><\/authors><\/contributors><titles><title>Pemoline-associated hepatic injury.<\/title><secondary-title><\/secondary-title><\/titles><dates><year>1990<\/year><\/dates><electronic-resource-num>10.1016\/0016-5085(90)91186-a<\/electronic-resource-num><\/record>\n<record><database name=\"MolGod\">MolGod<\/database><source-app name=\"MOL-GOD\" version=\"3.1.4\">MOL-GOD<\/source-app><rec-number>4<\/rec-number><ref-type name=\"Journal Article\">17<\/ref-type><contributors><authors><author>et al.<\/author><\/authors><\/contributors><titles><title>Pemoline-associated fulminant liver failure: testing the evidence for causation.<\/title><secondary-title><\/secondary-title><\/titles><dates><year>1995<\/year><\/dates><electronic-resource-num>10.1016\/0009-9236(95)90233-3<\/electronic-resource-num><\/record>\n<record><database name=\"MolGod\">MolGod<\/database><source-app name=\"MOL-GOD\" version=\"3.1.4\">MOL-GOD<\/source-app><rec-number>5<\/rec-number><ref-type name=\"Journal Article\">17<\/ref-type><contributors><authors><\/authors><\/contributors><titles><title>Effectiveness of risk management plans: a case study of pemoline using pharmacy claims data.<\/title><secondary-title><\/secondary-title><\/titles><dates><year>2007<\/year><\/dates><electronic-resource-num>10.1002\/pds.1279<\/electronic-resource-num><\/record>\n<record><database name=\"MolGod\">MolGod<\/database><source-app name=\"MOL-GOD\" version=\"3.1.4\">MOL-GOD<\/source-app><rec-number>6<\/rec-number><ref-type name=\"Journal Article\">17<\/ref-type><contributors><authors><\/authors><\/contributors><titles><title>Pemoline-associated hepatic failure: a critical analysis of the literature.<\/title><secondary-title><\/secondary-title><\/titles><dates><year>1997<\/year><\/dates><electronic-resource-num>10.1016\/s0887-8994(96)00266-4<\/electronic-resource-num><\/record>\n<record><database name=\"MolGod\">MolGod<\/database><source-app name=\"MOL-GOD\" version=\"3.1.4\">MOL-GOD<\/source-app><rec-number>7<\/rec-number><ref-type name=\"Journal Article\">17<\/ref-type><contributors><authors><author>et al.<\/author><\/authors><\/contributors><titles><title>Pemoline effects on children with ADHD: a time-response by dose-response analysis on classroom measures.<\/title><secondary-title><\/secondary-title><\/titles><dates><year>1995<\/year><\/dates><electronic-resource-num>10.1097\/00004583-199511000-00018<\/electronic-resource-num><\/record>\n<record><database name=\"MolGod\">MolGod<\/database><source-app name=\"MOL-GOD\" version=\"3.1.4\">MOL-GOD<\/source-app><rec-number>8<\/rec-number><ref-type name=\"Journal Article\">17<\/ref-type><contributors><authors><\/authors><\/contributors><titles><title>Pharmacodynamics of pemoline in attention deficit disorder with hyperactivity.<\/title><secondary-title><\/secondary-title><\/titles><dates><year>1992<\/year><\/dates><electronic-resource-num>10.1097\/00004583-199203000-00010<\/electronic-resource-num><\/record>\n<record><database name=\"MolGod\">MolGod<\/database><source-app name=\"MOL-GOD\" version=\"3.1.4\">MOL-GOD<\/source-app><rec-number>9<\/rec-number><ref-type name=\"Journal Article\">17<\/ref-type><contributors><authors><author>et al.<\/author><\/authors><\/contributors><titles><title>A randomized controlled trial of pemoline for attention-deficit\/hyperactivity disorder in substance-abusing adolescents.<\/title><secondary-title><\/secondary-title><\/titles><dates><year>2004<\/year><\/dates><electronic-resource-num>10.1097\/00004583-200404000-00008<\/electronic-resource-num><urls><related-urls><url>http:\/\/www.jaacap.org\/article\/S089085670961248X\/pdf<\/url><\/related-urls><\/urls><\/record>\n<record><database name=\"MolGod\">MolGod<\/database><source-app name=\"MOL-GOD\" version=\"3.1.4\">MOL-GOD<\/source-app><rec-number>10<\/rec-number><ref-type name=\"Journal Article\">17<\/ref-type><contributors><authors><author>et al.<\/author><\/authors><\/contributors><titles><title>Response to growth hormone in attention deficit hyperactivity disorder: effects of methylphenidate and pemoline therapy.<\/title><secondary-title><\/secondary-title><\/titles><dates><year>1998<\/year><\/dates><electronic-resource-num>10.1542\/peds.102.s3.497<\/electronic-resource-num><\/record>\n<record><database name=\"MolGod\">MolGod<\/database><source-app name=\"MOL-GOD\" version=\"3.1.4\">MOL-GOD<\/source-app><rec-number>11<\/rec-number><ref-type name=\"Journal Article\">17<\/ref-type><contributors><authors><author>et al.<\/author><\/authors><\/contributors><titles><title>Determination of levamisole, aminorex, and pemoline in plasma by means of liquid chromatography-mass spectrometry and application to a pharmacokinetic study of levamisole.<\/title><secondary-title><\/secondary-title><\/titles><dates><year>2014<\/year><\/dates><electronic-resource-num>10.1002\/dta.1619<\/electronic-resource-num><\/record>\n<record><database name=\"MolGod\">MolGod<\/database><source-app name=\"MOL-GOD\" version=\"3.1.4\">MOL-GOD<\/source-app><rec-number>12<\/rec-number><ref-type name=\"Journal Article\">17<\/ref-type><contributors><authors><author>George S. Grosser<\/author><author>Lee Sirois<\/author><author>Richard C. Sprinthall<\/author><\/authors><\/contributors><titles><title>Magnesium Pemoline: Activation of Extinction Responding after Continuous Reinforcement<\/title><secondary-title>SAGE Publications<\/secondary-title><\/titles><dates><year>1967<\/year><\/dates><electronic-resource-num>10.2466\/pr0.1967.21.1.11<\/electronic-resource-num><\/record>\n<record><database name=\"MolGod\">MolGod<\/database><source-app name=\"MOL-GOD\" version=\"3.1.4\">MOL-GOD<\/source-app><rec-number>13<\/rec-number><ref-type name=\"Journal Article\">17<\/ref-type><contributors><authors><author>Bostic<\/author><author>Jeff<\/author><author>Abrantes<\/author><author>Ana<\/author><author>Biederman<\/author><author>Joseph et al.<\/author><\/authors><\/contributors><titles><title>Controlled trial of high doses of pemoline for adults with attention-deficit\/hyperactivity disorder<\/title><secondary-title><\/secondary-title><\/titles><dates><year>2011<\/year><\/dates><\/record>\n<record><database name=\"MolGod\">MolGod<\/database><source-app name=\"MOL-GOD\" version=\"3.1.4\">MOL-GOD<\/source-app><rec-number>14<\/rec-number><ref-type name=\"Journal Article\">17<\/ref-type><contributors><authors><author>van der Laan JW<\/author><\/authors><\/contributors><titles><title>Dependence liability of Pemoline (Cylert R): a review<\/title><secondary-title>Rijksinstituut voor Volksgezondheid en Milieu RIVM<\/secondary-title><\/titles><dates><year>2017<\/year><\/dates><\/record>\n<record><database name=\"MolGod\">MolGod<\/database><source-app name=\"MOL-GOD\" version=\"3.1.4\">MOL-GOD<\/source-app><rec-number>15<\/rec-number><ref-type name=\"Journal Article\">17<\/ref-type><contributors><authors><\/authors><\/contributors><titles><title>GLC determination of pemoline in biological fluids.<\/title><secondary-title><\/secondary-title><\/titles><dates><year>1978<\/year><\/dates><electronic-resource-num>10.1002\/jps.2600670343<\/electronic-resource-num><\/record>\n<record><database name=\"MolGod\">MolGod<\/database><source-app name=\"MOL-GOD\" version=\"3.1.4\">MOL-GOD<\/source-app><rec-number>16<\/rec-number><ref-type name=\"Journal Article\">17<\/ref-type><contributors><authors><\/authors><\/contributors><titles><title>Intensive and sustained air operations: potential use of the stimulant, pemoline.<\/title><secondary-title><\/secondary-title><\/titles><dates><year>1998<\/year><\/dates><\/record>\n<record><database name=\"MolGod\">MolGod<\/database><source-app name=\"MOL-GOD\" version=\"3.1.4\">MOL-GOD<\/source-app><rec-number>17<\/rec-number><ref-type name=\"Journal Article\">17<\/ref-type><contributors><authors><author>Soyka<\/author><author>Michael<\/author><author>Till Krauseneck<\/author><author>Michael Soyka et al.<\/author><\/authors><\/contributors><titles><title>Delusional parasitosis associated with pemoline<\/title><secondary-title>Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen<\/secondary-title><\/titles><dates><year>2005<\/year><\/dates><electronic-resource-num>10.1159\/000085352<\/electronic-resource-num><urls><related-urls><url>https:\/\/core.ac.uk\/download\/16432277.pdf<\/url><\/related-urls><\/urls><\/record>\n<record><database name=\"MolGod\">MolGod<\/database><source-app name=\"MOL-GOD\" version=\"3.1.4\">MOL-GOD<\/source-app><rec-number>18<\/rec-number><ref-type name=\"Journal Article\">17<\/ref-type><contributors><authors><author>J Gordon Millichap<\/author><\/authors><\/contributors><titles><title>Acute Hepatic Failure with Pemoline (Cylert)<\/title><secondary-title>Pediatric Neurology Briefs<\/secondary-title><\/titles><dates><year>1998<\/year><\/dates><electronic-resource-num>10.15844\/pedneurbriefs-12-1-14<\/electronic-resource-num><urls><related-urls><url>https:\/\/www.pediatricneurologybriefs.com\/articles\/2351<\/url><\/related-urls><\/urls><\/record>\n<record><database name=\"MolGod\">MolGod<\/database><source-app name=\"MOL-GOD\" version=\"3.1.4\">MOL-GOD<\/source-app><rec-number>19<\/rec-number><ref-type name=\"Journal Article\">17<\/ref-type><contributors><authors><author>J Gordon Millichap<\/author><\/authors><\/contributors><titles><title>Analysis of Pemoline-Associated Hepatic Failure<\/title><secondary-title>Pediatric Neurology Briefs<\/secondary-title><\/titles><dates><year>1997<\/year><\/dates><electronic-resource-num>10.15844\/pedneurbriefs-11-3-6<\/electronic-resource-num><urls><related-urls><url>https:\/\/www.pediatricneurologybriefs.com\/articles\/2375<\/url><\/related-urls><\/urls><\/record>\n<record><database name=\"MolGod\">MolGod<\/database><source-app name=\"MOL-GOD\" version=\"3.1.4\">MOL-GOD<\/source-app><rec-number>20<\/rec-number><ref-type name=\"Journal Article\">17<\/ref-type><contributors><authors><author>J Gordon Millichap<\/author><\/authors><\/contributors><titles><title>Pemoline in ADHD<\/title><secondary-title>Pediatric Neurology Briefs<\/secondary-title><\/titles><dates><year>1995<\/year><\/dates><electronic-resource-num>10.15844\/pedneurbriefs-9-11-2<\/electronic-resource-num><urls><related-urls><url>https:\/\/www.pediatricneurologybriefs.com\/articles\/2557<\/url><\/related-urls><\/urls><\/record>\n<\/records><\/xml>\n"